Skip to Main Content

Paper Details

Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1.
Transplant Cell Ther
13
2021
BuMel, Busulfan, Children, High-Risk Neuroblastoma, Melphalan, Patients, SOS, busulfan, children, high, melphalan, neuroblastoma, patients, sinusoidal obstruction syndrome, stem cell
Author NameAffiliation
Rochelle BagatellChildren's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania
Steven G DuBoisDana-Farber / Boston Children's Cancer and Blood Disorder Center and Harvard Medical School
Yael P MosseChildren's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania
Stephan A GruppChildren's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania
Michael D HogartyChildren's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania
Julie M Gastier-FosterInstitute for Genomic Medicine, Nationwide Children's Hospital and Departments of Pathology and Pediatrics, Ohio State University College of Medicine
Julie M Gastier-FosterInstitute for Genomic Medicine, Nationwide Children's Hospital and Departments of Pathology and Pediatrics, Ohio State University College of Medicine
  • 1 - 7

Datasets

Release 1.2